Sponsored by:
Equine asthma affects many horses to varying degrees and can ultimately inhibit performance and cause quality of life concerns. This month the signs, causes, diagnostic and treatment options for equine asthma will be presented during the College of Veterinary Medicine s Equine Seminar Series, on Tuesday, April 20, from 6 to 7 p.m. via Zoom.
WHAT: Joy Tomlinson, DVM, DACVIM Large Animal Internal Medicine Specialists and Research Associate will talk about the signs and causes of equine asthma along with diagnostic and treatment options.
WHEN: Tuesday, April 20, 2021, 6 – 7 p.m.
Presenter Dr. Tomlinson received her DVM from Cornell University in 2010 and completed a large animal internal medicine residency at New Bolton Center, University of Pennsylvania in 2014. She has been a clinician at Cornell s Equine Hospital since 2014. Dr. Tomlinson is also a Research Associate at the Baker Institute for Animal Health in the Van de Walle lab.
Cuteness aside, the CDC advises that you not put face masks on animals As the population rushes to become vaccinated, there are still reported cases of infection, some of them not human. Today, the Pittsburgh Zoo & PPG Aquarium announced that two female lions have tested positive for SARS-CoV-2, the virus that causes COVID-19 in humans. A press release says the big cats likely contracted the virus after being exposed to an asymptomatic zoo employee. “The risk of infection between zoo animals and guests is very low, as we do not allow any of our visitors to come within close proximity to any of our cats, says Dr. Barbara Baker, president and CEO of Pittsburgh Zoo & PPG Aquarium.
Applied DNA Sciences : and Evvivax Announce Positive Preliminary Results of Phase I Clinical Trial for LinearDNA™ COVID-19 Vaccine Candidate in Felines marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
Applied DNA Sciences, Inc. and Takis Biotech/Evvivax: Applied DNA and Evvivax Announce Positive Preliminary Results of Phase I Clinical Trial for LinearDNA COVID-19 Vaccine Candidate in Felines
- Strong Neutralizing Antibody Titer Elicited Across Cohort - Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA or the Company ), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, and its program development partner, Evvivax, S.R.L. ( Evvivax ), today announced positive preliminary Phase I clinical trial results for a LinearDNA COVID-19 vaccine candidate (the vaccine candidate ) in adult domestic felines. Results following administration of a single prime dose of the vaccine candidate on day 1 in late February indicate that the LinearDNA vaccine candidate is well-tolerated by the cohort. A SARS-CoV-2 neutralization assay was conducted by the Cornell University Animal Health Diagnostic Center at the College of Veterinary Medicine 20 days after prime dose delivery
EXPANDING URBAN AGRICULTURE IN NYC ourtimepress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ourtimepress.com Daily Mail and Mail on Sunday newspapers.